Question |
Location of Relevant Content |
1 |
Community preparedness |
2 |
Community preparedness |
3 |
What type of pathology do cholinesterase inhibitors cause? |
4 |
What type of pathology do cholinesterase inhibitors cause? |
5 |
Nicotine acetylcholine receptors |
6 |
Nicotine acetylcholine receptors |
7 |
Nicotine acetylcholine receptors |
8 |
Muscarinic acetylcholine receptors |
9 |
What is the cholinergic toxidrome? |
10 |
Effects on routine laboratory tests |
11 |
Differential diagnosis |
12 |
Signs and symptoms: differences in pediatric cases |
13 |
Who is at risk for exposure? The exposure history |
14 |
Who is at risk for exposure? The exposure history |
15 |
Effects on routine laboratory tests |
16 |
Management strategy 2: Supportive care |
17 |
Management strategy 3: Medications - Atropine |
18 |
Management strategy 3: Medications |
19 |
Management strategy 3: Medications |
20 |
Management strategy 3: Medications |
21 |
Management strategy 3: Medications – 2-PAM |
22 |
Management strategy 3: Medications |
23 |
Management strategy 3: Medications |
24 |
Management strategy 3: Medications - Diazepam |
25 |
Syrup of ipecac, gastric lavage, cathartics, and activated charcoal |
26 |
The intermediate syndrome |
27 |
Organophosphate-induced delayed neuropathy (OPIDN) |
28 |
Organophosphorus ester-induced chronic neurotoxicity (OPICN) |
29 |
Other issues related to cholinesterase inhibitor toxicity |
30 |
The intermediate syndrome |
31 |
Muscarinic acetylcholine receptors |
32 |
Clinical findings are due to a mixture of nicotinic and muscarinic effects |
33 |
Clinical findings are due to a mixture of nicotinic and muscarinic effects |
34 |
Who is at risk for exposure? The exposure history |
35 |
What are cholinesterase inhibitors? |
36 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
37 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
38 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
39 |
The cholinergic toxidrome: What is the cholinergic toxidrome? |
40 |
The cholinergic toxidrome: Clinical findings in cholinesterase inhibitor toxicity are due to a mixture of nicotinic and muscarinic effects.
The cholinergic toxidrome: Signs and Symptoms: differences in pediatric cases |
41 |
Management strategy 2: supportive care |
42 |
Laboratory Assessment of the Cholinergic Toxidrome: Red Blood Cell (RBC) and Serum Cholinesterase Levels |
43 |
Laboratory Assessment of the Cholinergic Toxidrome: Direct Measurement of Cholinesterase Inhibitors and Their Metabolic Byproduct |
44 |
Management of the Cholinergic Toxidrome: Management Strategy 1: Prevention of Secondary Exposure |
45 |
Public Health and Medico-Legal Issues |